Skip to main content
J

JCR Pharmaceuticals Co.,Ltd. — Investor Relations & Filings

Ticker · 4552 ISIN · JP3701000006 LEI · 353800IMIU9CQ1DGOS14 T Manufacturing
Open in API
Filings indexed 61 across all filing types
Latest filing 2025-11-14 Regulatory Filings
Country JP Japan
Listing T 4552

About JCR Pharmaceuticals Co.,Ltd.

https://www.jcrpharm.co.jp/en/site/en/

JCR Pharmaceuticals is a global specialty biopharmaceutical company focused on the research, development, manufacturing, and commercialization of treatments for rare and genetic diseases. The company's portfolio includes therapies for conditions such as growth disorders, Mucopolysaccharidosis II (Hunter syndrome), and Fabry disease. A primary area of innovation involves developing treatments for central nervous system (CNS) disorders by utilizing proprietary technology to deliver biotherapeutics across the blood-brain barrier. JCR also develops and sells regenerative medicine products, aiming to address complex healthcare challenges and provide new treatment options for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is titled '確認書' (Confirmation Letter) and explicitly references '金融商品取引法第24条の５の２第１項' (Article 24-5-2, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification regarding the accuracy of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a report (like a semi-annual report), should be classified as Regulatory Filings (RNS) rather than the report itself. H1 51
2025-11-14 Japanese
半期報告書－第51期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 1% confidence The document is a '半期報告書' (Semi-Annual Report) filed under the Financial Instruments and Exchange Act of Japan. It contains comprehensive financial statements, including the balance sheet, income statement, and cash flow analysis for the interim period (April 1, 2025, to September 30, 2025). It is a formal regulatory filing containing substantive financial data, which fits the definition of an Interim/Quarterly Report (IR). H1 51
2025-11-14 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report) and explicitly states in Section 1 that it is being filed pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were passed at the company's 50th Annual General Meeting (AGM) held on June 25, 2025. Section 2 details the resolutions, which concern the election of directors and auditors. This structure—an official filing reporting the results of a shareholder meeting—aligns perfectly with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Although it relates to the AGM, the content is the official voting outcome report, not the AGM presentation materials (AGM-R). The document length is short (2358 chars), but its purpose is reporting definitive results, not announcing a future report, so the RPA/RNS rule does not apply here.
2025-06-27 Japanese
確認書
Audit Report / Information Classification · 1% confidence The document text contains Japanese characters and includes the title "有価証券報告書（通常方式）" which translates to "Securities Report (Normal Method)". It also references the Financial Instruments and Exchange Act ("金融商品取引法") and confirms the accuracy of the annual securities report ("有価証券報告書") for the fiscal year ending March 31, 2025, signed by the Representative Director Chairman and President. In the context of US SEC filings, the comprehensive annual report is the 10-K. While this is a Japanese filing, the content is clearly the annual statutory report confirming its accuracy, which aligns most closely with the purpose of a 10-K (Annual Report) or potentially a comprehensive Audit Report (AR) if it were solely the auditor's opinion, but the context points to the company certifying its annual filing. Given the options, the comprehensive annual report classification (10-K) is the best fit for a certified annual filing document, even if the specific Japanese form name differs from the US standard. FY 2025
2025-06-25 Japanese
内部統制報告書－第50期(2024/04/01－2025/03/31)
Governance Information Classification · 1% confidence The document is titled "内部統制報告書" (Internal Control Report) and explicitly references the legal basis as "金融商品取引法第24条の４の４第１項" (Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act). It details the scope, criteria, and procedures for evaluating internal controls over financial reporting as of the fiscal year-end (March 31, 2025), concluding that the internal controls are effective. This structure and content precisely match the requirements for an Audit Report/Information filing, specifically concerning internal controls, which aligns best with the 'Audit Report / Information (AR)' category, as it is a formal report on internal control effectiveness, distinct from a full Annual Report (10-K) or a simple Earnings Release (ER).
2025-06-25 Japanese
有価証券報告書－第50期(2024/04/01－2025/03/31)
Annual Report Classification · 1% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains a cover page detailing the fiscal year (50th term, 2024-04-01 to 2025-03-31), the company name (JCR Pharmaceuticals), and regulatory filing information. The presence of XBRL tags and comprehensive financial reporting structure confirms it is the official annual report. FY 2025
2025-06-25 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.